Apollomics, Inc. (APLM)Healthcare | Biotechnology | Foster City, United States | NasdaqCM
13.90 USD
-0.37
(-2.593%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 13.59 -0.31 (-0.310%) ⇩ (April 17, 2026, 4:53 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:11 p.m. EDT
Despite a potential catalyst in the form of a $2.0M bridge financing announcement, APLM presents a high-risk trap: negative fundamentals with -$26.64 EPS, ongoing regulatory uncertainty (Nasdaq hearing), and a downtrend confirmed by recent price action trading below all major moving averages. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.106103 |
| AutoETS | 0.107927 |
| AutoARIMA | 0.107929 |
| AutoTheta | 0.230434 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 16.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.074 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 6.285 |
| Market Cap | 29,844,758 |
| Forward P/E | -21.38 |
| Beta | 1.83 |
| Website | https://www.apollomicsinc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3519459 |
| Address1 | 989 East Hillsdale Blvd. |
| Address2 | Suite 220 |
| All Time High | 4,900.0 |
| All Time Low | 3.659 |
| Ask | 20.8 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 14,850 |
| Average Daily Volume3 Month | 10,638 |
| Average Volume | 10,638 |
| Average Volume10Days | 14,850 |
| Beta | 1.832 |
| Bid | 15.0 |
| Bid Size | 5 |
| Book Value | -3.986 |
| City | Foster City |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.9 |
| Current Ratio | 0.967 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 14.35 |
| Day Low | 13.37 |
| Display Name | Apollomics |
| Ebitda | -26,359,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.53 |
| Enterprise To Revenue | 2.017 |
| Enterprise Value | 13,980,537 |
| Eps Forward | -0.65 |
| Eps Trailing Twelve Months | -26.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 288 1674 |
| Fifty Day Average | 18.19642 |
| Fifty Day Average Change | -4.296421 |
| Fifty Day Average Change Percent | -0.23611353 |
| Fifty Two Week Change Percent | 135.19458 |
| Fifty Two Week High | 42.12 |
| Fifty Two Week High Change | -28.22 |
| Fifty Two Week High Change Percent | -0.6699905 |
| Fifty Two Week Low | 3.659 |
| Fifty Two Week Low Change | 10.240999 |
| Fifty Two Week Low Change Percent | 2.798852 |
| Fifty Two Week Range | 3.659 - 42.12 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,637,937,000,000 |
| Float Shares | 590,302 |
| Forward Eps | -0.65 |
| Forward P E | -21.384615 |
| Free Cashflow | -14,440,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 6,930,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 1.06121 |
| Held Percent Institutions | 0.00404 |
| Implied Shares Outstanding | 2,147,105 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-03-30 |
| Language | en-US |
| Last Fiscal Year End | 1,735,603,200 |
| Last Split Date | 1,732,492,800 |
| Last Split Factor | 1:100 |
| Long Business Summary | Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California. |
| Long Name | Apollomics, Inc. |
| Market | us_market |
| Market Cap | 29,844,758 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_382083491 |
| Most Recent Quarter | 1,751,241,600 |
| Net Income To Common | -31,188,000 |
| Next Fiscal Year End | 1,767,139,200 |
| Non Diluted Market Cap | 29,844,759 |
| Open | 14.297 |
| Operating Cashflow | -20,379,000 |
| Operating Margins | -1.248 |
| Payout Ratio | 0.0 |
| Phone | 650 209 4055 |
| Post Market Change | -0.30999947 |
| Post Market Change Percent | -2.230212 |
| Post Market Price | 13.59 |
| Post Market Time | 1,776,459,195 |
| Previous Close | 14.27 |
| Price Hint | 2 |
| Price To Book | -3.487205 |
| Price To Sales Trailing12 Months | 4.306603 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.905 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.37000084 |
| Regular Market Change Percent | -2.5928578 |
| Regular Market Day High | 14.35 |
| Regular Market Day Low | 13.37 |
| Regular Market Day Range | 13.37 - 14.35 |
| Regular Market Open | 14.297 |
| Regular Market Previous Close | 14.27 |
| Regular Market Price | 13.9 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 8,648 |
| Return On Assets | -0.72288 |
| Return On Equity | -3.8013299 |
| Revenue Growth | 3.808 |
| Revenue Per Share | 6.285 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,147,105 |
| Shares Percent Shares Out | 0.004 |
| Shares Short | 8,562 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,471 |
| Short Name | Apollomics Inc. |
| Short Percent Of Float | 0.0045 |
| Short Ratio | 1.62 |
| Source Interval | 15 |
| State | CA |
| Symbol | APLM |
| Total Cash | 2,100,000 |
| Total Cash Per Share | 1.903 |
| Total Debt | 744,000 |
| Total Revenue | 6,930,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -26.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.223595 |
| Two Hundred Day Average Change | -1.323595 |
| Two Hundred Day Average Change Percent | -0.08694366 |
| Type Disp | Equity |
| Volume | 8,648 |
| Website | https://www.apollomicsinc.com |
| Zip | 94,404 |